NCT01143805View on ClinicalTrials.gov

A Study To Estimate The Amount Of CP-690,550 (Study Drug) That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of CP-690,550 In Tablet Form

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Healthy
Interventions
DRUG

Tasocitinib 10 mg oral tablet

Treatment A: Single-dose of tasocitinib (CP-690,550) (10 mg) in the form of an oral tablet

DRUG

Tasocitinib 10 mg IV Infusion

Treatment B: Single-dose of tasocitinib (CP-690,550) (10 mg) in the form of a 30 minute intravenous infusion

Trial Locations (1)

188770

Pfizer Investigational Site, Singapore

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY